Lung Transplantation for Lymphangioleiomyomatosis: The French Experience
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare disease, leading in some cases to end-stage respiratory failure. Lung transplantation (LT) represents a therapeutic option in advanced pulmonary LAM. METHODS: We conducted a retrospective multicenter study of 44 patients who underwent LT for LAM at 9 centers in France between 1988 and 2006. RESULTS: All patients were women with a mean age of 41+/-10 years at LT. There were 34 single-lung transplants and 11 bilateral transplants (one retransplantation). Prior clinical events related to LAM were present in 75% of the patients and previous thoracic surgical procedures were noted in 86.6% of cases. At the latest preoperative evaluation, 30 patients had an obstructive pattern (mean forced expiratory volume in 1 second: 26%+/-14% of predicted) and 15 had a combined restrictive and obstructive pattern, with a mean KCO=27%+/-8.8% of predicted, PaO2=52.8+/-10.4 and PaCO2=42.6+/-9.8 mm Hg. Intraoperative cardiopulmonary bypass was required in 13 cases. The length of mechanical ventilation was 7.5+/-12.8 days. The median duration of follow-up was 37 months. The 1, 2, 5, and 10 years survival rates were 79.6%, 74.4%, 64.7%, and 52.4%, respectively. Extensive pleural adhesions were found in 21 patients leading to severe intraoperative hemorrhage. Postoperative LAM-related complications were pneumothorax in the native lung in five patients, chylothorax in six, bronchial dehiscence or stenosis in seven. There were two cases of recurrence of LAM. CONCLUSION: Despite a high morbidity mainly caused by previous surgical interventions and disease-related complications, LT is a satisfactory therapeutic option for end-stage respiratory failure in LAM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant hemorrhage arising from angiomyolipomas is uncommon peri-operatively and their presence should not preclude candidacy for lung transplant.(311, 314)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [311]
In the citing paper
“Fewer patients with LAM have required lung transplant since the standardized use of mTOR inhibitors as treatment, but it remains an indication for those with severely abnormal lung function (FEV1 < 30%), exertional dyspnea (NYHA class III or IV), or hypoxemia at rest.(303–306, 308–315)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [311]
In the citing paper
“While disease recurrence does occur post-transplant, it does not appear to limit survival.(303, 304, 309, 311, 316–318)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [311]
Citations
Cites
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253 · cited 12×
“Although the recent published results of therapy with the mammalian target of rapamycin (mTOR) inhibitor, sirolimus hold promise especially as a treatment of angiomyolipoma (AML) (4), enthusiasm about the pulmonary function results should be tempered (5) and justify the need for larger clinical trials using such thera…”
BackgroundInfluentialOrens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Trulock, E. P., Christie, J. D., Edwards, L. B., Boucek, M. M., Aurora, P., Taylor, D. O., Dobbels, F., Rahmel, A. O., Keck, B. M., & Hertz, M. I. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.06.003 · Cited by 485 · cited 6×
“In the 2007 registry of ISHLT (6), there were mostly bilateral procedures in LAM patients (59 SLT vs. 116 BLT).”
BackgroundInfluentialKitaichi, M., Nishimura, K., Itoh, H., & Izumi, T. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842216 · Cited by 362
Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients
Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., & Valeyre, D. (1999) · Medicine · doi:10.1097/00005792-199909000-00004 · Cited by 329 · cited 1×
“It is characterized by respiratory symptoms such as dyspnea, cough, hemoptysis, but complications such as pneumothoraces or chylous effusions and ascitis can reveal the disease (2, 3).”
Recurrent Lymphangiomyomatosis after Transplantation: Genetic Analyses Reveal a Metastatic Mechanism
Karbowniczek, M., Astrinidis, A., Balsara, B. R., Testa, J. R., Lium, J. H., Colby, T. V., McCormack, F. X., & Henske, E. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-969oc · Cited by 254 · cited 2×
“Recent genetic analysis of these cases indicated that benign LAM cells migrate by metastatic mechanism to form new lesions in multiple organs and in the allograft (29).”
BackgroundLung Transplantation for Lymphangioleiomyomatosis
Boehler, A., Speich, R., Russi, E. W., & Weder, W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610243351704 · Cited by 217
Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis
Davies, D. M., Johnson, S. R., Tattersfield, A. E., Kingswood, J. C., Cox, J. A., McCartney, D. L., Doyle, T., Elmslie, F., Saggar, A., de Vries, P. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmc072500 · Cited by 211 · cited 2×
“Although the recent published results of therapy with the mammalian target of rapamycin (mTOR) inhibitor, sirolimus hold promise especially as a treatment of angiomyolipoma (AML) (4), enthusiasm about the pulmonary function results should be tempered (5) and justify the need for larger clinical trials using such thera…”
BackgroundJohnson, S. R. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00113303 · Cited by 209
Lung Transplantation for Pulmonary Langerhans' Cell Histiocytosis: A Multicenter Analysis
Dauriat, G., Mal, H., Thabut, G., Mornex, J.-F., Bertocchi, M., Tronc, F., Leroy-Ladurie, F., Dartevelle, P., Reynaud-Gaubert, M., Thomas, P., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000200304.64613.af · Cited by 188 · cited 1×
“Like other systemic diseases such as Langerhans’ cell histiocytosis (24) and sarcoidosis (25), LAM could recur in the allograft but the recurrence rate seems to be much lower than for the other mentioned diseases.”
BackgroundSelf-citation
Cited by
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
“If one includes prior chest tube insertion, the percentage of referred patients may be up to 40%(3,4) or for up to 90% in conditions such as lymphangioleiomyomatosis (LAM).(4) Surgery may be coincidental, for instance, previous CABG, but usually is related as a diagnostic or therapeutic step in pre-transplant manageme…”
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
Johnson, S. R., Cordier, J. F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00076209 · Cited by 590
Self-citationGupta, N., Finlay, G. A., Kotloff, R. M., Strange, C., Wilson, K. C., Young, L. R., Taveira-DaSilva, A. M., Johnson, S. R., Cottin, V., Sahn, S. A., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1965st · Cited by 253
“11) (44, 56, 57), and there was a trend toward such patients being more likely to have pleural adhesions (65% vs.”
BackgroundLung transplantation: indications and contraindications
Weill, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.141 · Cited by 137
“There have been small series (14 and 18 patients) (5,6) describing successful lung transplant after chest surgery.”
BackgroundInfluentialPulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients
Cottin, V., Harari, S., Humbert, M., Mal, H., Dorfmüller, P., Jaïs, X., Reynaud-Gaubert, M., Prevot, G., Lazor, R., Taillé, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00093111 · Cited by 96
Self-citationPulmonary Lymphangioleiomyomatosis
Zhang, X., & Travis, W. D. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0576-rs.1 · Cited by 59
Piccari, L., Allwood, B., Antoniou, K., Chung, J. H., Hassoun, P. M., Nikkho, S. M., Saggar, R., Shlobin, O. A., Vitulo, P., Nathan, S. D., et al. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12213 · Cited by 54
“The prevalence of PH in LAM varies widely from around 8% in general cohorts66–68 to as high as 45% in pretransplant patients.(69) PH is severe in approximately 20% of cases(68) and is associated with worse dyspnea and exercise tolerance,(66) right heart failure, and haemoptysis.”
BackgroundKhawar, M. U., Yazdani, D., Zhu, Z., Jandarov, R., Dilling, D. F., & Gupta, N. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.015 · Cited by 45
Hagaman, J. T., Schauer, D. P., McCormack, F. X., & Kinder, B. W. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200910-1553oc · Cited by 45
Lung Transplantation for lymphangioleiomyomatosis in Japan
Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146749 · Cited by 37
“In three multi-center studies, the incidences of pneumothorax in native lungs, chylothorax and ascites were 7–14%, 7–14%, and 2%, respectively [6, 16, 17].”
BackgroundKlarquist, J. S., Barfuss, A. J., Kandala, S., Reust, M. J., Braun, R. K., Hu, J. C. C., Dilling, D. F., McKee, M. D., Boissy, R. E., Love, R. B., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090525 · Cited by 38
Ryu, J. H., Tian, X., Baqir, M., & Xu, K. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0269-z · Cited by 36
World Health Organization Group 5 Pulmonary Hypertension
Lahm, T., & Chakinala, M. M. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.08.005 · Cited by 37
“In contrast, an RHC study of 20 patients with LAM evaluated for lung transplantation documented PH in 45% of patients.(130) As in other lung diseases, the prevalence of PH in LAM seems to increase with worsening severity of lung disease.”
MethodManagement of lymphangioleiomyomatosis
Taveira‐DaSilva, A. M., & Moss, J. (2014) · F1000Prime Reports · doi:10.12703/p6-116 · Cited by 35
“The five-year post-transplant survival of LAM patients undergoing lung transplantation was around 69% [116–119].”
BackgroundPulmonary Hypertension in Diffuse Parenchymal Lung Diseases
Shlobin, O. A., Brown, A. W., & Nathan, S. D. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.08.002 · Cited by 30
Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis
Ussavarungsi, K., Hu, X., Scott, J. P., Erasmus, D. B., Mallea, J. M., Alvarez, F., Lee, A. S., Keller, C. A., Ryu, J. H., & Burger, C. D. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.08.014 · Cited by 26
Weatherald, J. C., Savale, L., & Humbert, M. J. C. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0783-5 · Cited by 24
Machuca, T. N., Losso, M. J., Camargo, S. M., Schio, S. M., Melo, I. A., Hochhegger, B., Felicetti, J. C., & Camargo, J. J. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.12.051 · Cited by 22
Barrera, E. A., Franch, N. M., Vera-Sempere, F. J., & Alarcón, J. P. (2011) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2010.08.008 · Cited by 22
Pulmonary lymphangioleiomyomatosis (LAM): A literature overview and case report
Cong, C.-V., Anh, T.-T. T., Ly, T.-T., & Đức, N. M. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.02.075 · Cited by 18
“[30] Martine Reynaud-Gaubert, Jean-François Mornex, Hervé Mal, Michèle Treilhaud, Claire Dromer, Sébastien Quétant, et al.”
BackgroundInfluentialSingle lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan
Oishi, H., Watanabe, T., Matsuda, Y., Noda, M., Ejima, Y., Saiki, Y., Seyama, K., Kondo, T., & Okada, Y. (2018) · Surgery Today · doi:10.1007/s00595-018-1678-z · Cited by 17
French recommendations for the diagnosis and management of lymphangioleiomyomatosis
Cottin, V., Blanchard, É., Kerjouan, M., Lazor, R., Reynaud‐Gaubert, M., Taillé, C., Uzunhan, Y., Wémeau-Stervinou, L., Andréjak, C., Baud, D., et al. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101010 · Cited by 24
“Lung transplantation in patients with a history of thoracic or pleural surgery is not contraindicated [11], and must be discussed by the medical and surgical team on a case-by-case basis (the bene fi t-risk ratio must be assessed) [93 − 98].”
Self-citationMoavero, R., Romagnoli, G., Graziola, F., & Curatolo, P. (2015) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2015.10.006 · Cited by 17
Baldi, B. G., Samano, M. N., Campos, S. V., de Oliveira, M. R., Junior, J. E. A., Carraro, R. M., Teixeira, R. H. O. B., Minguini, I. P., Burlina, R., Pato, E. Z. S., et al. (2017) · Lung · doi:10.1007/s00408-017-0045-y · Cited by 16
Current management of lymphangioleiomyomatosis
Taillé, C., Borie, R., & Crestani, B. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349ac8c · Cited by 16
Kurosaki, T., Otani, S., Miyoshi, K., Okazaki, M., Sugimoto, S., Suno, M., Yamane, M., Kobayashi, M., Oto, T., & Toyooka, S. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13108 · Cited by 15
Lung transplantation for lymphangioleiomyomatosis
Warrior, K., & Dilling, D. F. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.021 · Cited by 15
Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.
Sathirareuangchai, S., Shimizu, D. M., & Vierkoetter, K. R. (2020) · PubMed · Cited by 15
Résultats de la transplantation pulmonaire
Quétant, S., Rochat, T., & Pison, C. M. (2010) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.08.001 · Cited by 16
Self-citationRecurrence of primary disease following lung transplantation
Esendagli, D. R., Ntiamoah, P., Küpeli, E., Bhardwaj, A., Ghosh, S., Mukhopadhyay, S., & Mehta, A. C. (2022) · ERJ Open Research · doi:10.1183/23120541.00038-2022 · Cited by 14
Sélection des candidats à la transplantation pulmonaire en France en 2019
Falque, L., Gheerbrant, H., Saint‐Raymond, C., Quétant, S., Camara, B., Briault, A., Porcu, P., Pirvu, A., Durand, M., Pison, C. M., et al. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.03.009 · Cited by 13
Self-citationCystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function
Daccord, C., Nicod, L. P., & Lazor, R. (2017) · Respiration · doi:10.1159/000485106 · Cited by 12
Zhang, J., Liu, D., Yue, B., Ban, L., Zhou, M., Wang, H., Lv, J., Wu, B., Zhai, Z., Xu, K., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.584826 · Cited by 11
Nakagiri, T., Shintani, Y., Minami, M., Inoue, M., Funaki, S., Kawamura, T., & Okumura, M. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.04.103 · Cited by 10
“The rate has been reported to be 14% to 16% [9,21].”
BackgroundAcute Constrictive Pericarditis After Lung Transplantation for Lymphangioleiomyomatosis
Billings, M. E., Mulligan, M. S., & Raghu, G. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.10.009 · Cited by 11
“Chylothorax after lung transplantation for AM is well described but not common,(14) occurring in % to 9% of patients.(4,6) Pericardial effusions have been escribed in LAM patients after lung transplantation, but here have been no reports of confirmed chylous effuions.”
Management of Pulmonary Hypertension Due to Chronic Lung Disease
Sugarman, J. A., & Weatherald, J. C. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/zkut3813 · Cited by 9
Lymphangioléiomyomatose pulmonaire : de la physiopathologie à la prise en charge
Chebib, N., Khouatra, C., Lazor, R., Archer, F., Leroux, C., Gamondes, D., Thivolet-Béjui, F., Cordier, J. F., & Cottin, V. (2015) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2015.10.005 · Cited by 11
Quand le pneumologue doit-il envisager la greffe pulmonaire pour un de ses patients ?
Philippe, B., Dromer, C., Mornex, J., Velly, J.-F., & Stern, M. (2009) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(09)74047-1 · Cited by 10
Self-citationBarrera, E. A., Franch, N. M., Cuesta, J. C. P., Vera-Sempere, F. J., & Alarcón, J. P. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.01.021 · Cited by 7
Bassi, I., Hollis, G., Cottin, V., Harari, S. A., Zwanenburg, E., Veltkamp, M., Casanova, Á., Fletcher, M. J., Masefield, S. C., Powell, P., et al. (2016) · ERJ Open Research · doi:10.1183/23120541.00102-2015 · Cited by 8
COLT : 10 ans de recherche en transplantation pulmonaire, résultats et perspectives
Tissot, A., Foureau, A., Brosseau, C., Danger, R., Roux, A., Bernasconi, E., Gomez, C., Durand, M., Renaud-Picard, B., Pavec, J. L., et al. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.06.007 · Cited by 7
“[2] Reynaud-Gaubert M, Mornex J-F, Mal H, Treilhaud M, Dromer”
BackgroundSelf-citationTaveira‐DaSilva, A. M., & Moss, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11475-8 · Cited by 8
A Case Report of Lymphangioleiomyomatosis Presenting as Spontaneous Pneumothorax
Riojas, R. A., Bahr, B. A., Thomas, D. B., Perciballi, J., & Noyes, L. (2012) · Military Medicine · doi:10.7205/milmed-d-11-00333 · Cited by 6
Disease-specific approach to lung transplantation
Knoop, C., & Estenne, M. (2009) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283303607 · Cited by 7
Taveira‐DaSilva, A. M., Gopalakrishnan, V., Yao, J., Chen, M. Y., Julien-Williams, P. A., Jones, A. M., Pacheco–Rodriguez, G., & Moss, J. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02123-7 · Cited by 6
Lymphangioleiomyomatosis: A Review
Konkol, S. (2022) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2022.17.002320 · Cited by 4
Beyond the Graft: Recurrence of Interstitial Lung Diseases Post Transplant
Ntiamoah, P., & Mehta, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041093 · Cited by 4
Trasplante pulmonar en la linfangioleiomiomatosis esporádica. Estudio de 7 casos
Barrera, E. A., Franch, N. M., Cuesta, J. C. P., Vera-Sempere, F. J., & Alarcón, J. P. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.05.036 · Cited by 4
Mesenchymal and miscellaneous neoplasms
Allen, T. C., Cagle, P. T., & Flieder, D. B. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139018760.036 · Cited by 3
Barrera, E. A., Franch, N. M., Vera-Sempere, F. J., & Alarcón, J. P. (2011) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(11)70019-2 · Cited by 8
Lung Transplantation: Selection of Candidates
Thomas, C., Williams, M., & Shlobin, O. A. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2304197 · Cited by 2
Recipient selection for lung transplantation: perspective in decision-making
Sarıbaş, E., & Çitak, S. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae144 · Cited by 3
Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases
Jutant, E., Ghigna, M., Montani, D., & Humbert, M. J. C. (2020) · European Respiratory Society eBooks · doi:10.1183/2312508x.10028119 · Cited by 2
Pulmonary Hypertension in Orphan Lung Diseases
Montani, D., Thoré, P., Jutant, E., & Humbert, M. J. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_41 · Cited by 2
Addas, R. A., Thumerel, M., Jougon, J., Delcambre, F., & Jean-Francois, V. (2013) · Open Journal of Thoracic Surgery · doi:10.4236/ojts.2013.32007 · Cited by 2
Pulmonary Hypertension in Orphan Lung Diseases
Montani, D., Girerd, B., Seferian, A., Godinas, L., & Humbert, M. J. C. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_33 · Cited by 2
Towards Therapy in Genetic Kidney Diseases: Hopes and Uncertainties
Grünfeld, J. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05461008 · Cited by 1
Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations
Weatherald, J. C., Montani, D., & Sitbon, O. (2020) · Respiratory medicine · doi:10.1007/978-3-030-43435-9_6 · Cited by 2
Руководство Европейского респираторного общества по диагностике и лечению лимфангиолейомиоматоза
Джонсон, С. Р., Кордье, Д. Ф., Лазор, К., Коттен, В., Костабель, У., Харари, С., Рено-Габер, М., Болер, А., Броне, М., Поппер, Х., et al. (2010) · PULMONOLOGIYA · doi:10.18093/0869-0189-2010-6-9-23 · Cited by 2
Paciente con esclerosis tuberosa y angiomiolipomas renales
Segrelles, G., de Tejada, J. A. G. R., Gómez-Punter, R. M., Fernandes, G. C. D. O., Vázquez, E. G. D. M., & Girón, R. M. (2010) · Revista de Fomento Social · doi:10.1016/s1576-9895(10)34008-2 · Cited by 1
Mesenchymal Tumors of the Lung
Weissferdt, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-36438-0_14 · Cited by 1
Perioperative management of thoracic surgery in patients with lymphangioleiomyomatosis
Fukui, M., Seyama, K., Matsunaga, T., Hattori, A., Takamochi, K., Oh, S., Kawagoe, I., & Suzuki, K. (2022) · Surgical Case Reports · doi:10.1186/s40792-022-01507-5 · Cited by 1
“Prolonged air leakage has been reported in approximately 10–24% cases of post-transplant complications [12, 15, 16].”
Coleman, D. M. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_163 · Cited by 1
Rozpoznanie i leczenie limfangioleiomiomatozy (LAM) z grupy PEComa
Sobiborowicz, A., Czarnecka, A. M., Szumera‐Ciećkiewicz, A., Rutkowski, P. L., & Świtaj, T. (2021) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0034 · Cited by 1
Pulmonary hypertension in orphan lung diseases
Montani, D., Kularatne, M., Jutant, E., & Humbert, M. J. C. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018522 · Cited by 2
Enfermedades pulmonares intersticiales poco frecuentes
Navarro, J. G., & Bendito, A. S. (2010) · Elsevier eBooks · doi:10.1016/b978-84-8086-298-1.50033-0
Philippe, B., Dromer, C., Mornex, J. F., Velly, J.-F., & Stern, M. (2009) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(09)74065-3
Self-citationIndications de la transplantation pulmonaire en médecine interne
Mal, H. (2011) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.09.014
Self-citationSpecialistiche, S. M. (2012)
Lymphangioleiomyomatosis Is a Systemic Disorder Related to Mutated Tuberous Sclerosis Complex
Belchis, D. (2014) · Pathology Case Reviews · doi:10.1097/pcr.0000000000000028
“Recurrence of LAM in the transplanted lung is unusual.(34) More recently, treatment with mTOR inhibitors has shown promise.”
BackgroundPulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension
Huston, J., Hatton, N. D., & Ryan, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_3
Epidemiology of Pulmonary Hypertension: From Quaternary Referral Centre to the Community
Choudhary, G., & Ventetuolo, C. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_4
Pulmonary Hypertension in Rare Parenchymal Lung Diseases
Shlobin, O. A., & Nathan, S. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_10
Ajani, S., & Kotloff, R. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-91184-7_3
Lung Transplantation for Obstructive Lung Diseases
Rigby, A. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_13
Interstitial lung disease: course report
Kreuter, M., & Poberezhets, V. (2020) · Breathe · doi:10.1183/20734735.0075-2020
“Lung transplantation should be performed according to the established procedure, recurrence of LAM is possible and may be treated with sirolimus, but at the same time, sirolimus is contraindicated at the early phase of transplantation [6, 7].”
BackgroundPulmonary Hypertension Associated with Respiratory Diseases
Kolb, T. M., & Hassoun, P. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_207-1
Lung Transplantation: Recipient Selection
Glanville, A. R., & Ainge‐Allen, H. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00082-2
Pulmonary Hypertension Associated with Respiratory Disease
Kolb, T. M., & Hassoun, P. M. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_207
Aspectos atuais sobre a seleção de pacientes candidatos a transplante pulmonar
de Figueiredo, B. Q., Júnior, Á. N. M., Andrade, A. C. A., Julio, B. R., Nunes, F. M., Ferreira, H. H. D. S., da Cunha, L. L. P., Lemos, M. A. G., & Araujo, Y. C. (2022) · Research Society and Development · doi:10.33448/rsd-v11i15.37130
Transplantation pulmonaire et lymphangioléiomyomatose
Reynaud‐Gaubert, M., Pavec, J. L., & Uzunhan, Y. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.01.023
Self-citationMaladies kystiques pulmonaires de l’adulte d’origine génétique
Diesler, R., Ahmad, K., Chalabreysse, L., Glérant, J.-C., Harzallah, I., Touraine, R. L., Si-Mohamed, S. A., & Cottin, V. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.08.005
Rare pulmonary diseases and pulmonary hypertension
Tagariello, F., Elia, D., & Harari, S. A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001188 · Cited by 1
Taveira‐DaSilva, A. M., Gopalakrishnan, V., Yao, J., Chen, M. Y., Julien-Williams, P. A., Jones, A. M., Pacheco–Rodriguez, G., & Moss, J. (2022) · Figshare · doi:10.6084/m9.figshare.21203398
Pulmonary Vascular Disease Associated with Other Parenchymal Lung Diseases
Louw, E. H., van Heerden, J. K., Buckley, A., & Allwood, B. (2025) · Respiratory medicine · doi:10.1007/978-3-032-03581-3_12
Metadata
- Authors
- Reynaud-Gaubert, M., Mornex, J.-F., Mal, H., Treilhaud, M., Dromer, C., Quétant, S., Leroy-Ladurie, F., Guillemain, R., Philit, F., Dauriat, G., Grenet, D., & Stern, M.
- Affiliations
- Hôpital Louis Pradel (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Hôpital Albert Michallon (FR)
- Hôpital Marie Lannelongue (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Foch (FR)
- Venue
- Transplantation
- Published
- 2008-08-27
- Volume
- 86
- Issue
- 4
- Pages
- 515-520
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2055288244
- Semantic Scholar
- 10f8cf3b79aa9476e25f53768ce8e3ca2933a97c
- Cited by
- 87
- References
- 30
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 7 · 2022: 9 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 8 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lymphangioleiomyomatosis, lung transplantation, end-stage respiratory failure, postoperative complications, chylothorax, pneumothorax, bronchial stenosis, pleural adhesions, survival, bilateral lung transplantation, retransplantation
- MeSH terms
- Adult, Biopsy, Female, France, Histocompatibility Testing, Humans, Intraoperative Complications, Functional Laterality, Lung Neoplasms, Middle Aged, Oxygen Consumption, Surveys and Questionnaires, Respiratory Function Tests, Retrospective Studies, Smoking, Lung Transplantation, Treatment Outcome, Treatment Failure, Lymphangioleiomyomatosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.